arrow
S

Satoshi Morita

kyoto university
H指数:85
被引数:4.0万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Phase I and early phase II study of enhancing immune checkpoint inhibitor efficacy using a Mycobacterium tuberculosis extract combined with radiation therapy in non-small cell lung cancer patients: NEJ046A

I期和早期II期研究:在非小细胞肺癌患者中使用结核分枝杆菌提取物联合放射疗法增强免疫检查点抑制剂疗效:NEJ046A

2026-10-180
PRE
Treatment sequence after first-line immunotherapy in older adults with advanced NSCLC (NEJ057)

老年晚期非小细胞肺癌患者一线免疫治疗后治疗方案(NEJ057)

2026-10-030
PRE
Clinical value of prostate-specific antigen halving time as a predictor of response to first-line systemic treatment for synchronous metastatic castration-sensitive prostate cancer

前列腺特异性抗原半衰期作为同步转移性去势敏感前列腺癌一线系统性治疗效果预测指标的临床价值

2026-08-250
PRE
Efficacy and safety of eribulin mesylate vs. docetaxel or paclitaxel, combined with trastuzumab and pertuzumab, as first-line treatment for HER2-positive locally advanced or metastatic breast cancer: updated subgroup analyses of JBCRG-M06/EMERALD

甲磺酸艾瑞布林与多西他赛或紫杉醇联合曲妥珠单抗和帕妥珠单抗作为HER2阳性局部晚期或转移性乳腺癌的一线治疗的疗效和安全性:JBCRG-M06/EMERALD研究的更新亚组分析

2026-07-080
PRE
Quality-of-life assessment in the randomized JBCRG-M06/EMERALD study of eribulin plus dual HER2 blockade in HER2-positive locally advanced or metastatic breast cancer

在JBCRG-M06/EMERALD研究中评估厄洛替尼联合双重HER2阻断在HER2阳性局部晚期或转移性乳腺癌中的生活质量评估

2026-06-100
PRE
Association between serum lactate dehydrogenase level and renal outcome in patients with advanced chronic kidney disease without diabetes mellitus

血清乳酸脱氢酶水平与无糖尿病的晚期慢性肾脏病患者肾功能结局的关系

2026-06-010
PRE
Health-related quality of life with pertuzumab retreatment: Secondary analysis of the PRECIOUS trial

接受帕妥珠单抗再治疗患者的生活质量:PRECIOUS试验的二次分析

Breast
IF7.9
2026-05-230
OAAI
Reduced-fluence photodynamic therapy versus placebo for central serous chorioretinopathy (REPLAY trial): rationale and study protocol of a pivotal double-blind randomised controlled trial

低能量光动力疗法与安慰剂治疗中心性浆液性脉络膜视网膜病变(REPLAY试验):一项关键性双盲随机对照试验的方案和原理

2026-04-210
PRE
Risk Stratification Based on Imaging Findings for Pregnancies With Subamniotic or Subchorionic Hematoma on Placental MRI

根据胎盘MRI羊膜下或绒毛膜下血肿的影像学表现进行风险分层

2026-01-010
PRE
Real-world multicenter study of immune checkpoint inhibitors in advanced cervical cancer across HPV-associated and HPV-independent subtypes

真实世界中免疫检查点抑制剂在HPV相关和HPV非相关亚型晚期宫颈癌中的多中心研究

2025-11-260
PRE
Lung immune prognostic index as a biomarker for predicting the benefit of immune checkpoint inhibitor plus chemotherapy in older patients with non-small cell lung cancer: a secondary analysis of the NEJ057 study

肺癌免疫预后指数作为预测免疫检查点抑制剂联合化疗在非小细胞肺癌老年患者中获益的生物标志物:NEJ057研究的二次分析

2025-11-050
PRE
Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2024 for the treatment of colorectal cancer

Kinugasa, Y.; Uehara, K.; Yamaguchi, K.; Saito, Y.; Murofushi, K.; Sugai, T.; Ishiguro, M.; Ishihara, S.; Ueno, H.; Oka, S.; 等. 日本结直肠癌协会(JSCCR). 日本结直肠癌协会2024年结直肠癌治疗指南. 国际临床肿瘤学杂志, 2025, 30, 2410–2463. [Google Scholar] [CrossRef]

2025-11-011
PRE
Neutrophils predominate as IL1B-expressing cells in Schnitzler syndrome: Insights from the SCan study to evaluate the efficacy and safety of canakinumab in Japanese patients

中性粒细胞作为IL1B表达细胞在施尼茨综合征中占主导地位:来自SCan研究对日本患者中卡那奴单抗疗效和安全性的评估见解

2025-10-012
OAAI
Durvalumab, carboplatin, and etoposide in patients who are treatment-naive with extensive-stage small-cell lung cancer and poor performance status (NEJ045A): a single-arm phase 2 trial

度鲁妥单抗、卡铂和依托泊苷用于治疗初治广泛期小细胞肺癌且体力状况较差的患者(NEJ045A):一项单臂Ⅱ期试验

2025-09-280
PRE